Psyence Biomed, a division of Psyence that specializes in natural psilocybin products, has entered a conditional share sale agreement to acquire an 11.1% stake in PsyLabs, a psychedelic active pharmaceutical ingredient development company, for USD 1.1 million in stock.
The acquisition will further strengthen Psyence Biomed's existing partnership with PsyLabs by granting exclusive access to PsyLabs’ nature-derived psilocybin supply and continuing the collaborative development of psychedelic-based therapeutics.
PsyLabs specializes in producing pharmaceutical-grade psychoactive compounds, including psilocybin, ibogaine, and mescaline. The company has developed a proprietary process for producing high-purity, naturally derived psilocybin and is commercially licensed for the production and export of these compounds.
Analyst QuickTake: Psyence Biomed continues to actively mark its presence in the psilocybin therapeutics space . Earlier this month, it acquired Clairvoyant Therapeutics for USD 2.8 million to expand its pipeline. In July 2024, it secured a USD 25 million stock purchase agreement with White Lion Capital to fund Phase IIb clinical trials.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.